The campus “will help the company substantially increase future manufacturing capacity with state-of-the-art equipment and processes to produce high quality products for decades to come,” spokesperson Michele Rest told Biopharma-Reporter.
The 350,000 square foot site will employ up to 500 people once the facility is fully operational, said Rest.
Rest told us the facility will manufacture products currently made at another Californian site.
“Our La Verne campus will manufacture all of the products currently being made in San Dimas, as well as any new products launched by Gilead going forward.”
Rest said the first product to be manufactured at the La Verne plant is AmBisome (amphotericin B) liposome for injection, which treats fungal and parasitic infections.
“Our La Verne facility will also package, label and distribute more than 20 different product brands, including our cure for hepatitis C, as well as treatment for hepatitis B and HIV/AIDS,” she added.